Evidence map›Paper›PMID 26361572›Full record

ArticleNanotechnology reviews2012

Can nanotechnology potentiate photodynamic therapy?

Ying-Ying Huang, Sulbha K Sharma, Tianhong Dai, Hoon Chung, Anastasia Yaroslavsky, Maria Garcia-Diaz, Julie Chang, Long Y Chiang, Michael R Hamblin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanotechnology reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ying-Ying HuangWellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom St., Boston, MA 02114, USA ; Department of Dermatology, Harvard Medical School, Boston, MA, USA ; Aesthetic and Plastic Center, Guangxi Medical University, Nanning, China.
Sulbha K SharmaWellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom St., Boston, MA 02114, USA.
Tianhong DaiWellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom St., Boston, MA 02114, USA ; Department of Dermatology, Harvard Medical School, Boston, MA, USA.
Hoon ChungWellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom St., Boston, MA 02114, USA ; Department of Dermatology, Harvard Medical School, Boston, MA, USA.
Anastasia YaroslavskyWellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom St., Boston, MA 02114, USA ; College of Engineering, Boston University, Boston, MA, USA.
Maria Garcia-DiazWellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom St., Boston, MA 02114, USA ; Institut Químic de Sarrià, Universitat Ramon Llull, Barcelona 08017, Spain.
Julie ChangWellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom St., Boston, MA 02114, USA ; Department of Chemistry, Harvard University, Boston, MA, USA.
Long Y ChiangDepartment of Chemistry, University of Massachusetts, Lowell, MA, USA.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom St., Boston, MA 02114, USA ; Department of Dermatology, Harvard Medical School, Boston, MA, USA ; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA.

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
New Stereoregular Functionalized Fullerenes as Nanomedicines for PDTR01CA137108 · NCI · UNIVERSITY OF MASSACHUSETTS LOWELL · PI CHIANG, LONG Y. · 2009 to 2012
$1.3M
NCI NIH HHS R01 CA137108NIAID NIH HHS R01 AI050875
6 · The paper itself

Abstract

Photodynamic therapy (PDT) uses the combination of non-toxic dyes and harmless visible light to produce reactive oxygen species that can kill cancer cells and infectious microorganisms. Due to the tendency of most photosensitizers (PS) to be poorly soluble and to form nonphotoactive aggregates, drug-delivery vehicles have become of high importance. The nanotechnology revolution has provided many examples of nanoscale drug-delivery platforms that have been applied to PDT. These include liposomes, lipoplexes, nanoemulsions, micelles, polymer nanoparticles (degradable and nondegradable), and silica nanoparticles. In some cases (fullerenes and quantum dots), the actual nanoparticle itself is the PS. Targeting ligands such as antibodies and peptides can be used to increase specificity. Gold and silver nanoparticles can provide plasmonic enhancement of PDT. Two-photon excitation or optical upconversion can be used instead of one-photon excitation to increase tissue penetration at longer wavelengths. Finally, after sections on

Indexed as

dendrimerfullerenegraphenelipoplexlipoproteinliposomemagnetic nanoparticlemicellenanocellnanoparticleORMOSILpolymeric nanoparticleporphysomequantum dotsingle-walled carbon nanotubetwo-photon excitationupconversion

Identifiers

PMID26361572
PMCPMC4562697

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.